Pneumococcal Testing Market

Pneumococcal Testing Market - Key Research Findings

1. The global pneumococcal testing market in 2019 was valued at US$ 1.1 Bn.
2. Growth in the prevalence of pneumococcal diseases, increase in adoption of diagnostic measures, recent advances in pneumococcal diagnostics and increase in technological innovation with development of nucleic acid detection tests for major pneumonia pathogens and immune-chromatographic pneumococcal urinary antigen tests are the primary factors for the growth of pneumococcal testing market.
3. Rise in awareness about the benefits of early diagnosis among the patient population has increased the number of diagnostic tests are the factors expected for the driving the market growth.
   • Collectively, Europe and North America, will account for more than half of the revenue shares in the Pneumococcal Testing market by the end of 2030.
4. North America will continue to be a prominent regional market for pneumococcal testing due to the increasing prevalence of pneumococcal diseases and recent advancement in diagnostic test.
5. The confirmed caseloads of the COVID-19 in the US have surpassed that of the European countries - Italy, and Spain - emerging as the ground zero of the pandemic. The US FDA has approved molecular diagnostic, and ELISA kits for emergency use authorization (EUA) to spot the nucleic acid from SARS-CoV-2, the virus behind COVID-19.
6. Point of Care (POC) testing remains highly preferred method of pneumococcal testing. POC testing accounted for a major revenue share in 2019, and is projected to maintain the trend throughout the forecast period.
   • Point of Care Testing growing at a significant growth rate owing to its delivering the results in real time which help physician to make a correct and better decision in treatment of diseases.  
7. Hospitals and clinics will continue to be the most prominent end users of pneumococcal testing. This is attributed to the availability of pneumococcal testing kits and skilled personnel for better clinical management of various diseases across several medical domains
8. Enzyme Linked Immunosorbent Assay (ELISA) accounted for a significant revenue share in the market owing to its high sensitivity and specificity and convenience of performing compared to other methods.

Key Factors Shaping the Pneumococcal Testing Market

Rise in Incidents of Pneumococcal Diseases

The major clinical syndromes of pneumococcal disease are pneumonia, bacteremia, and meningitis. As per Centers for Diseases Control and Prevention 2017, estimates that 150,000 hospitalizations from pneumococcal pneumonia occur annually in the United States. Pneumococci account for up to 30% of adult community-acquired pneumonia.

Bacteremia occurs in up to 25-30% of patients with pneumococcal pneumonia. The case-fatality rate is 5-7% and may be much higher among elderly persons. Complications of pneumococcal pneumonia include empyema, pericarditis, and respiratory failure. In Europe and the USA, S. pneumoniae is the most common cause of community-acquired bacterial pneumonia in adults.

Recent Advances in Molecular Test for the Diagnosis of Pneumococcal Bacteria

Molecular diagnostic tests have been the single major development in pneumonia diagnostics over recent years. Nucleic acid detection tests (NATs) have greatly improved the ability to detect respiratory viruses and bacterial pathogens that do not normally colonize the respiratory tract. NATs have several advantages over other existing diagnostic tools. They potentially detect low levels of all-known pneumonia pathogens in clinical specimens.

There are now a wide variety of user-friendly platforms that have enabled NATs to be deployed in laboratories outside of specialist tertiary referral centers. Although NATs have mainly focused on detecting the presence of a particular microorganism, they may also provide additional information, such as data on antimicrobial resistance and strain typing.

Shift from Single-Analyte Testing to Multiplex Testing

Molecular diagnostic testing has moved toward a broader syndromic screening approach. This trend is the result of sophisticated technologies that enable the detection of >1 analyte at a time. Test devices vary from low multiplex (2-5 analytes) to 25 or more different analytes, often now combining a mixture of pathogen types, and also antibiotic resistance markers.

New highly multiplexed cartridge-based systems can detect the majority of bacterial pathogens that cause community, ventilator-associated, and hospital-acquired pneumonia within 1-2 hours. In addition, these systems can detect >20 antibiotic resistance genetic markers. The intent is to provide a POC early diagnosis that can lead to more focused appropriate antimicrobial therapy.

Growth of the Market in Emerging Economies

Increasing prevalence of pneumococcal diseases, and other diseases in the Asia Pacific (APAC) are factors offering a strong impetus to the growth of the pneumococcal testing market. The launch of advanced molecular diagnostics testing prominently accounts for the growing popularity of pneumococcal testing across developing regional markets. Cconsistent rise in the number of manufacturers and distributors, is likely to contribute to the growth of the pneumococcal testing market in the near future.

Pneumococcal Testing Market Structure Analysis

• Major players focus on inorganic growth strategies to make a strong hold on targeted in-licensing and acquisitions through expanding its R&D activities and its distribution channels particularly including its specialist retail chains
• Prominent players continue to address the unmet needs in the market through continuous product technological innovation.
• The Pneumococcal Testing market is characterised as a consolidate market likely to remain dynamic, growing in steady pace throughout the forecast period. Approximately 65% - 80% share of the market is held by tier-1 players.

Report Scope